logo
Plus   Neg
Share
Email

J&J Plans To Execute All Levers Of Capital Allocation Strategy

Johnson & Johnson (JNJ) said that it plans to execute all levers of its capital allocation strategy to fund future growth opportunities while providing returns to shareholders. It plans to maximize potential of leading brands by filing more than 40 line extensions for regulatory approval through 2023.

The company noted that it will host a meeting today with industry analysts to review the strategy of its Janssen Pharmaceutical Companies to deliver above-market, compound annual growth through 2023.

The company plans to file for regulatory approval or launch at least 10 new medicines between 2019 and 2023.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Electronics retailer Best Buy Co., Inc. (BBY) reported Thursday a 27 percent increase in profit for the first quarter from last year, which was impacted by restructuring charges, and higher revenues. Both adjusted earnings per share and revenues for the quarter topped analysts' estimates. The company also provides guidance for the second quarter and reiterated its outlook for the full-year 2020. While reporting financial results for the second quarter on Thursday, Hormel Foods Corp. (HRL) lowered its earnings and net sales guidance for the full-year 2019. For fiscal 2019, the company now projects earnings in a range of $1.71 to $1.85 per share, and net sales between $9.70 billion and $10.20... NetApp Inc. (NTAP) Wednesday reported a fourth-quarter profit that fell short of Wall Street estimates, as revenues slipped 3 percent. Shares of the company slipped 6% in extended trading session after its first-quarter outlook was also short of current expectations. Sunnyvale, California-based NetApp...
Follow RTT